eigerbioadmin

»»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 76 blog entries.
24 07, 2017

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-07-24T12:02:26+00:00

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., July 24, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment [...]

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 2017-07-24T12:02:26+00:00
29 06, 2017

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

2017-06-30T18:22:25+00:00

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PALO ALTO and SAN DIEGO, Calif., June 29, 2017, Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a).  Financial terms of the agreement include a total upfront of $3.1 million in [...]

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals 2017-06-30T18:22:25+00:00
14 06, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors

2017-06-14T16:56:31+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors - Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif., June 14, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 2017-06-14T16:56:31+00:00
12 06, 2017

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

2017-06-12T14:46:00+00:00

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego - Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif., June 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for [...]

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 2017-06-12T14:46:00+00:00
6 06, 2017

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients

2017-06-06T13:20:42+00:00

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients PALO ALTO, Calif., June 6, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, today announced completion of enrollment of the Phase 2 multiple-ascending dose (MAD) study evaluating subcutaneous (SC) exendin [...]

Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 2017-06-06T13:20:42+00:00
30 05, 2017

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th

2017-05-30T12:02:59+00:00

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th PALO ALTO, Calif. – May 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at [...]

Eiger BioPharmaceuticals to Present at Jefferies 2017 Global Healthcare Conference June 7th 2017-05-30T12:02:59+00:00
17 05, 2017

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema

2017-05-17T13:43:24+00:00

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema - Data Supports Ongoing Phase 2 ULTRA Study of Ubenimex in Lymphedema PALO ALTO, Calif., May 17, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced publication in Science Translational Medicine (STM) the results of extensive preclinical studies of ubenimex in [...]

Eiger Announces Results Demonstrating Benefit of Ubenimex and Leukotriene B4 (LTB4) Modulation in Experimental Lymphedema 2017-05-17T13:43:24+00:00
15 05, 2017

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension

2017-05-15T14:39:47+00:00

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension - Phase 2 LIBERTY Data Expected First Quarter 2018 PALO ALTO, Calif., May 15, 2017 / PRNewswire / Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of [...]

Eiger BioPharmaceuticals Completes Enrollment of Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension 2017-05-15T14:39:47+00:00
12 05, 2017

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results

2017-05-12T12:53:17+00:00

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results — Five Phase 2 Programs in Four Orphan Indications Progressing — Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., May 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for the [...]

Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 2017-05-12T12:53:17+00:00
8 05, 2017

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago

2017-05-15T14:42:05+00:00

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago PALO ALTO, Calif., May 8, 2017 -- Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced HDV/HBV co-infection prevalence data from an International Classification of Diseases (ICD) analysis presented at Digestive Disease Week (DDW) in [...]

Eiger Announces Presentation of Prevalence Data of Hepatitis Delta Virus (HDV) Infection in the U.S. at Digestive Disease Week (DDW) in Chicago 2017-05-15T14:42:05+00:00